Braveheart Bio Q3 net loss narrows 55% to $26.5 million
BRVE•Braveheart Bio’s third-quarter 2026 net loss narrowed 55% year over year to $26.5 million. Cash, cash equivalents and investments totaled $503.5 million at September 30, with funding expected to last into 2029.
1. Quarterly results and trials
Braveheart Bio’s third-quarter 2026 net loss narrowed 55% year over year to $26.5 million, while operating expenses fell 49% to $30.15 million. The company had $503.5 million in cash, cash equivalents and investments at September 30, 2026, and expects funding to last into 2029. LIONHEART-HCM Phase 3 is enrolling patients, with interim results expected in the second half of 2027; NOBLEHEART-HCM Phase 3 and fixed-dose TRUEHEART-HCM Phase 2b remain scheduled to begin in the first half of 2027.
